Back to results
CompletedPhase 2

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

NCT00716092

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

1218.37.49003 Boehringer Ingelheim Investigational Site

Berlin, Germany

+2 additional locations

View on ClinicalTrials.gov
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients — TrialFind